EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

[1]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[2]  C. Bréchot,et al.  State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[4]  H. Hsu,et al.  Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. , 1985, Gastroenterology.

[5]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[6]  M. Ebara,et al.  Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. , 1986, Gastroenterology.

[7]  R. Purcell,et al.  Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. , 1987, Gastroenterology.

[8]  Y. Liaw,et al.  Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. , 1988, Gastroenterology.

[9]  J. Polio,et al.  Hepatocellular Carcinoma in Wilson's Disease Case Report and Review of the Literature , 1989, Journal of clinical gastroenterology.

[10]  A. Roche,et al.  A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. , 1990, Journal of hepatology.

[11]  P. Ghosh,et al.  Symptomatic reactivation of hepatitis B in pregnancy , 1991, The Lancet.

[12]  J. Belghiti,et al.  Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis , 1991, Annals of surgery.

[13]  D. V. van Thiel,et al.  Hepatic resection versus transplantation for hepatocellular carcinoma. , 1991, Annals of surgery.

[14]  R. Metcalf,et al.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.

[15]  L. Bolondi,et al.  Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival , 1992, Hepatology.

[16]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[17]  P. Prorok.  Epidemiologic Approach for Cancer Screening: Problems in Design and Analysis of Trials , 1992, The American journal of pediatric hematology/oncology.

[18]  A Morabito,et al.  Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients , 1992, Cancer.

[19]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[20]  S. Kawasaki,et al.  Surgery for small liver cancers. , 1993, Seminars in surgical oncology.

[21]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[22]  P. Brissot,et al.  Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. , 1993, Gastroenterology.

[23]  D. Pateron,et al.  Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. , 1994, Journal of hepatology.

[24]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[25]  T. Starzl,et al.  Liver Transplantation for Fulminant Hepatic Failure , 1985, Seminars in liver disease.

[26]  T. Livraghi,et al.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. , 1995, Radiology.

[27]  C. Bartolozzi,et al.  Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 western patients , 1995, Cancer.

[28]  S. Chevret,et al.  A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. , 1995, The New England journal of medicine.

[29]  C. Boland,et al.  Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. , 1995, Journal of the National Cancer Institute.

[30]  E. Schiff,et al.  Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. , 1995, Gastroenterology.

[31]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[32]  A. Burroughs,et al.  Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis , 1996, The Lancet.

[33]  F. Sarasin,et al.  Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. , 1996, The American journal of medicine.

[34]  J. Bruix,et al.  Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. , 1996, Gastroenterology.

[35]  C. Chastang,et al.  Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis , 1996, Hepatology.

[36]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[37]  W. Fetter,et al.  Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. , 1997, Vaccine.

[38]  H. Bismuth,et al.  Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. , 1997, Annals of surgery.

[39]  J. Pignon,et al.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. , 1998, Journal of hepatology.

[40]  Y. Nakanuma,et al.  Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. , 1998, Gastroenterology.

[41]  M. Makuuchi,et al.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure , 1998, Hepatology.

[42]  P Boffetta,et al.  A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma , 1998, International journal of cancer.

[43]  P. Rougier,et al.  Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Al-Ahwal,et al.  Chemoembolization in hepatocellular carcinoma. , 1998, Saudi medical journal.

[45]  H. Moriwaki,et al.  Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. , 1996, Digestion.

[46]  H. Moriwaki,et al.  Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma , 1998, Digestion.

[47]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[49]  J. Bruix,et al.  Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution , 1998, Hepatology.

[50]  P. Marcellin,et al.  Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment , 1999, Hepatology.

[51]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[52]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[53]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[54]  B. Yang,et al.  Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. , 1999, Journal of medical screening.

[55]  S. Chevret,et al.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. , 1999, Journal of hepatology.

[56]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[57]  J. Bruix,et al.  Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials , 1999, Hepatology.

[58]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[59]  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999 .

[60]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[61]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[62]  A. Moles,et al.  Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival , 2000, Hepatology.

[63]  A. Lok,et al.  Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy , 2000, Hepatology.

[64]  Yasuo Ohashi,et al.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.

[65]  D. Adams,et al.  Immunotherapy in hepatocellular carcinoma , 2000, The Lancet.

[66]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[67]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.

[68]  O. Farges,et al.  Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. , 2000, Journal of the American College of Surgeons.

[69]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[70]  H. Lee,et al.  Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea , 2000, Hepatology.

[71]  M. Makuuchi,et al.  Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan , 2000, Hepatology.

[72]  H. Yatsuhashi,et al.  Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. , 2000, Journal of hepatology.

[73]  D. Robinson,et al.  The protein tyrosine kinase family of the human genome , 2000, Oncogene.

[74]  B. McMahon,et al.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study , 2000, Hepatology.

[75]  S Munn,et al.  Live donors for liver transplantation? , 2000, The New Zealand medical journal.

[76]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[77]  P Neuhaus,et al.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis , 2001, Hepatology.

[78]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[79]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[80]  M. Bernardi,et al.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. , 2001, Journal of hepatology.

[81]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[82]  H. El‐Serag,et al.  The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans , 2001, American Journal of Gastroenterology.

[83]  C. Bréchot,et al.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? , 2001, Hepatology.

[84]  M. Monden,et al.  Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma , 2001, British Journal of Cancer.

[85]  S. Hadziyannis,et al.  Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. , 2001, Gastroenterology.

[86]  Y. Shiratori,et al.  Des‐γ‐carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma , 2001, Cancer.

[87]  T. Livraghi.  Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. , 1998, Hepato-gastroenterology.

[88]  J. Lim,et al.  Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. , 2001, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[89]  A. Heath,et al.  An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques , 2001, Vox sanguinis.

[90]  J. Bruix,et al.  Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. , 2001, Hepatology.

[91]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[92]  Sergi Ganau,et al.  Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma , 2001, Hepatology.

[93]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[94]  S. Hadziyannis,et al.  Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease , 2002, Hepatology.

[95]  R. Wiesner,et al.  The new liver allocation system: Moving toward evidence‐based transplantation policy , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[96]  M. Zoli,et al.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience) , 2002, American Journal of Gastroenterology.

[97]  Junji Konishi,et al.  Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. , 2002, Radiology.

[98]  L. Ellis,et al.  Simplified staging for hepatocellular carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  J. Bruix,et al.  Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.

[100]  J. Rodés,et al.  Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. , 2002, Gastroenterology.

[101]  R. Fontana,et al.  Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. , 2002, Gastroenterology.

[102]  K. Soo,et al.  High‐dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial , 2002, Hepatology.

[103]  K. Leung,et al.  Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system , 2002, Cancer.

[104]  J. Bruix,et al.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation , 2002, Gut.

[105]  G. Everson,et al.  Adult-to-adult transplantation of the right hepatic lobe from a living donor. , 2002, The New England journal of medicine.

[106]  P. Marcellin,et al.  Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. , 2002, Gastroenterology.

[107]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[108]  S. Fan,et al.  Extended Hepatic Resection for Hepatocellular Carcinoma in Patients with Cirrhosis: Is It Justified? , 2002, Annals of surgery.

[109]  S. H. Cheng,et al.  Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[110]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[111]  Carlo Bartolozzi,et al.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. , 2003, Radiology.

[112]  V. Paradis,et al.  Quantitative RT‐PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis , 2003, The Journal of pathology.

[113]  J. Marrero,et al.  Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients , 2003, Hepatology.

[114]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[115]  R. D. de Man,et al.  Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase , 2003, Gut.

[116]  S. Finkelstein,et al.  Microdissection‐based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma , 2003, Hepatology.

[117]  K. Boudjema,et al.  Adjuvant intra‐arterial injection of iodine‐131–labeled lipiodol after resection of hepatocellular carcinoma , 2003, Hepatology.

[118]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[119]  S. Kawasaki,et al.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.

[120]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[121]  H. Janssen,et al.  Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection , 2003, Journal of viral hepatitis.

[122]  E. Schiff,et al.  Durability of serologic response after lamivudine treatment of chronic hepatitis B , 2003, Hepatology.

[123]  M. Alter,et al.  Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[124]  L. Bolondi.  Screening for hepatocellular carcinoma in cirrhosis. , 2003, Journal of hepatology.

[125]  T. Arima,et al.  Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation , 2003, Cancer.

[126]  Y. Jeng,et al.  Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients , 2003, Hepatology.

[127]  V. Vilgrain,et al.  Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial , 2003, Annals of surgery.

[128]  D. Parkin,et al.  Screening for liver cancer: results of a randomised controlled trial in Qidong, China , 2003, Journal of medical screening.

[129]  M. Roncalli,et al.  Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. , 2003, Journal of hepatology.

[130]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[131]  E. Santagostino,et al.  A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. , 2003, Blood.

[132]  T. Poynard,et al.  Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. , 2003, Journal of hepatology.

[133]  L. Pączek,et al.  [Liver transplantation for hepatocellular carcinoma]. , 2003, Polskie Archiwum Medycyny Wewnetrznej.

[134]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[135]  S. D. Lee,et al.  Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. , 2003, Scandinavian journal of gastroenterology.

[136]  L. Rodrigo,et al.  Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis , 2003, Hepatology.

[137]  Carmen Ayuso,et al.  MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation , 2003, Hepatology.

[138]  Yi-Cheng Chen,et al.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. , 2004, Gastroenterology.

[139]  J. Dufour,et al.  Angiogenesis and hepatocellular carcinoma. , 2004, Journal of hepatology.

[140]  M. Makuuchi,et al.  Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey , 2004, Cancer.

[141]  M. Makuuchi,et al.  The surgical approach to HCC: Our progress and results in Japan , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[142]  J. Bruix,et al.  High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[143]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[144]  M. Giovannini,et al.  Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[145]  M. Makuuchi,et al.  Contrast‐enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[146]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[147]  E. Stelzl,et al.  Rapid Quantification of Hepatitis B Virus DNA by Automated Sample Preparation and Real-Time PCR , 2004, Journal of Clinical Microbiology.

[148]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[149]  M. Zoli,et al.  Surveillance for Hepatocellular Carcinoma in Elderly Italian Patients With Cirrhosis: Effects on Cancer Staging and Patient Survival , 2004, American Journal of Gastroenterology.

[150]  R. Purcell,et al.  Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. , 2004, Gastroenterology.

[151]  J. Bruix,et al.  Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma , 2004, Hepatology.

[152]  F. González‐Huix,et al.  Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis , 2004, Gut.

[153]  M. Torbenson,et al.  mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.

[154]  D. Samuel.  Management of hepatitis B in liver transplantation patients. , 2004, Seminars in liver disease.

[155]  M. Colombo,et al.  Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. , 2004, Gastroenterology.

[156]  L. Mariani,et al.  Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation: A Prospective Study , 2004, Annals of surgery.

[157]  Christian Bréchot,et al.  Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. , 2004, Gastroenterology.

[158]  M. Omata,et al.  Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. , 2004, Gastroenterology.

[159]  Issues in screening and surveillance for hepatocellular carcinoma. , 2004, Gastroenterology.

[160]  A. Lok.  Prevention of hepatitis B virus-related hepatocellular carcinoma. , 2004, Gastroenterology.

[161]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[162]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[163]  K. Pan,et al.  Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. , 2004, World journal of gastroenterology.

[164]  Sammy Saab,et al.  Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation , 2005, Hepatology.

[165]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[166]  R. D. de Man,et al.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy , 2005, Gut.

[167]  P. Rougier,et al.  Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  F. Roudot-thoraval,et al.  Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[169]  C-J. S. Lin,et al.  Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less , 2005, Gut.

[170]  J. Jang,et al.  Long-Term Results of Lamivudine Monotherapy in Korean Patients with HBeAg-Positive Chronic Hepatitis B: Response and Relapse Rates, and Factors Related to Durability of HBeAg Seroconversion , 2005, Intervirology.

[171]  Carlo Bartolozzi,et al.  Imaging diagnosis. , 2005, Seminars in liver disease.

[172]  P. Philip,et al.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  R. T. Ten Haken,et al.  Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  J. Marrero,et al.  Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.

[175]  R. Lencioni,et al.  Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead? , 2005, Journal of hepatology.

[176]  V. Mazzaferro,et al.  Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.

[177]  G. Gores,et al.  Hepatocellular carcinoma: molecular pathways and new therapeutic targets. , 2005, Seminars in liver disease.

[178]  George Kitis,et al.  Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine , 2005, Hepatology.

[179]  C. Broelsch,et al.  Liver resection for hepatocellular carcinoma in non‐cirrhotic liver without underlying viral hepatitis , 2005, The British journal of surgery.

[180]  Rita Golfieri,et al.  Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma , 2005, Hepatology.

[181]  Steven S Raman,et al.  Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. , 2005, Radiology.

[182]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[183]  Raymond T Chung,et al.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. , 2005, Journal of hepatology.

[184]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[185]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[186]  T. Mok,et al.  Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma (HCC). , 2005 .

[187]  Chien-Jen Chen,et al.  Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.

[188]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[189]  V. Soriano,et al.  Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. , 2002, AIDS.

[190]  Giorgio Palù,et al.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.

[191]  M. Kew.  Prevention of hepatocellular carcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[192]  L. Roberts,et al.  The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. , 2005, Journal of hepatology.

[193]  J. Marrero,et al.  Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. , 2005, Journal of hepatology.

[194]  R. Bruno,et al.  Natural history of chronic hepatitis B in co-infected patients. , 2006, Journal of hepatology.

[195]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[196]  A. Andriulli,et al.  Pegylated interferon alpha‐2b as monotherapy or in combination with ribavirin in chronic hepatitis delta , 2006, Hepatology.

[197]  Alona Muzikansky,et al.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  M. Colombo,et al.  The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients , 2006, Hepatology.

[199]  H. Janssen,et al.  Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype , 2006, The American Journal of Gastroenterology.

[200]  S. Thorgeirsson,et al.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.

[201]  E. Schiff,et al.  Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[202]  G. Casazza,et al.  Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.

[203]  P. Marcellin,et al.  Efficacy of peginterferon alpha‐2b in chronic hepatitis delta: Relevance of quantitative RT‐PCR for follow‐up , 2006, Hepatology.

[204]  P. Schirmacher,et al.  Dysregulation of growth factor signaling in human hepatocellular carcinoma , 2006, Oncogene.

[205]  T. Kawabe,et al.  Radiofrequency ablation for hepatocellular carcinoma in so‐called high‐risk locations , 2006, Hepatology.

[206]  Steven S Raman,et al.  Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters--pilot comparison with pathologic findings. , 2006, Radiology.

[207]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[208]  P. Rougier,et al.  Medical treatments for hepatocellular carcinoma (HCC): what's next? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[209]  M. Makuuchi,et al.  Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. , 2006, Gastroenterology.

[210]  E. Lesaffre,et al.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.

[211]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[212]  P. Pontisso,et al.  Virological Profiles in Hepatitis B Virus/Hepatitis C Virus Coinfected Patients under Interferon plus Ribavirin Therapy , 2006, Antiviral therapy.

[213]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[214]  Alessandro Vitale,et al.  Prospective validation of the Barcelona Clinic Liver Cancer staging system. , 2006, Journal of hepatology.

[215]  L. Mariani,et al.  Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis , 2006, Hepatology.

[216]  M. Manns,et al.  Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience , 2006, Journal of viral hepatitis.

[217]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  Recipient deaths during donor surgery: A new ethical problem in living donor liver transplantation (LDLT) , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[219]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[220]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[221]  P. Farci.  Treatment of chronic hepatitis D: New advances, old challenges , 2006, Hepatology.

[222]  D. Perlmutter,et al.  Pathogenesis of Chronic Liver Injury and Hepatocellular Carcinoma in Alpha-1-Antitrypsin Deficiency , 2006, Pediatric Research.

[223]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[224]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[225]  P. Pontisso,et al.  Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients , 2006, Hepatology.

[226]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[227]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[228]  V. Mazzaferro,et al.  Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: Questions, answers and demands for a common language , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[229]  E. Furth,et al.  Lack of benefit of pre‐transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[230]  R. Bruno,et al.  Prophylaxis and treatment of hepatitis B in immunocompromised patients. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[231]  C. Yurdaydın,et al.  A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis , 2007, Journal of viral hepatitis.

[232]  E. Schiff,et al.  Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[233]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[234]  H. Petrowsky,et al.  Strategies for safer liver surgery and partial liver transplantation. , 2007, The New England journal of medicine.

[235]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[236]  S. Thorgeirsson,et al.  Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. , 2007, Cancer research.

[237]  F. Zoulim,et al.  Characterization of a New Sensitive PCR Assay for Quantification of Viral DNA Isolated from Patients with Hepatitis B Virus Infections , 2007, Journal of Clinical Microbiology.

[238]  P. Lampertico,et al.  Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. , 2007, Gastroenterology.

[239]  A. Lok,et al.  Hepatocellular Carcinoma Recurrence and Death Following Living and Deceased Donor Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[240]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[241]  M. Kudo.  Review of 4th Single Topic Conference on HCC , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[242]  M. Zoli,et al.  Surveillance for Early Diagnosis of Hepatocellular Carcinoma: Is It Effective in Intermediate/Advanced Cirrhosis? , 2007, The American Journal of Gastroenterology.

[243]  M. Sherman,et al.  Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis , 2007, The American Journal of Gastroenterology.

[244]  I. Ng,et al.  Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma , 2007, The British journal of surgery.

[245]  A. Burroughs,et al.  Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. , 2007, Cancer treatment reviews.

[246]  M. Buti,et al.  Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis , 2007, Hepatology.

[247]  L. Terracciano,et al.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis , 2007, Hepatology.

[248]  N. Weiss,et al.  Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[249]  P. Hewson,et al.  Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. , 2007, Health technology assessment.

[250]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[251]  J. Roberts,et al.  Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative Imaging , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[252]  D. Shouval,et al.  Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies , 2007, British journal of haematology.

[253]  C. Porta,et al.  Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[254]  W. Lau,et al.  Partial Hepatectomy With Wide Versus Narrow Resection Margin for Solitary Hepatocellular Carcinoma: A Prospective Randomized Trial , 2007, Annals of surgery.

[255]  Derek Y. Chiang,et al.  Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.

[256]  C. Thio,et al.  Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. , 2007, The Lancet. Infectious diseases.

[257]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[258]  P. Marcellin,et al.  Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.

[259]  S. Boyault,et al.  Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas , 2007, Oncogene.

[260]  Patrice Cacoub,et al.  Meta-analyses of FibroTest diagnostic value in chronic liver disease , 2007, BMC gastroenterology.

[261]  G. Dore,et al.  Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database , 2007, Journal of gastroenterology and hepatology.

[262]  R. Lencioni,et al.  Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. , 2008, Journal of hepatology.

[263]  Yutaka Matsuyama,et al.  Development of evidence‐based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[264]  L. Bolondi,et al.  Liver Transplantation for Hepatocellular Carcinoma: Results of Down‐Staging in Patients Initially Outside the Milan Selection Criteria , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[265]  Raymond T Chung,et al.  Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[266]  M. Manns,et al.  The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. , 2008, Journal of hepatology.

[267]  Shou-Dong Lee,et al.  Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment , 2008, Journal of gastroenterology and hepatology.

[268]  Ryutaro Hirose,et al.  Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: An intention‐to‐treat analysis , 2008, Hepatology.

[269]  A. Benson,et al.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis , 2007, Hepatology.

[270]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[271]  J. Buckels,et al.  Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis , 2008, Gut.

[272]  Jean-Michel Pawlotsky,et al.  Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. , 2008, Gastroenterology.

[273]  R. D. de Man,et al.  Exacerbation of chronic hepatitis B infection after delivery , 2007, Journal of viral hepatitis.

[274]  J. Bruix,et al.  Novel advancements in the management of hepatocellular carcinoma in 2008. , 2008, Journal of hepatology.

[275]  N. Habib,et al.  Preoperative Portal Vein Embolization for Major Liver Resection: A Meta-Analysis , 2008, Annals of surgery.

[276]  J. Millis,et al.  Living donor liver transplantation: The ethics and the practice , 2007, Hepatology.

[277]  M. Kudo,et al.  Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score , 2008, Oncology.

[278]  G. Guyatt,et al.  Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive , 2008, BMJ : British Medical Journal.

[279]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[280]  H. Tsukuma,et al.  Declining Incidence of Hepatocellular Carcinoma in Osaka, Japan, from 1990 to 2003 , 2008, Annals of Internal Medicine.

[281]  M. D’Onofrio,et al.  Comparison of Seven Staging Systems in Cirrhotic Patients With Hepatocellular Carcinoma in a Cohort of Patients Who Underwent Radiofrequency Ablation With Complete Response , 2008, The American Journal of Gastroenterology.

[282]  Jean-Michel Pawlotsky,et al.  Performance of the Cobas AmpliPrep/Cobas TaqMan Real-Time PCR Assay for Hepatitis B Virus DNA Quantification , 2008, Journal of Clinical Microbiology.

[283]  P. Marcellin,et al.  Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B , 2008, Hepatology.

[284]  G. Fattovich,et al.  Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.

[285]  C. Hsiung,et al.  A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial , 2008, Hepatology.

[286]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[287]  C. la Vecchia,et al.  Trends in mortality from hepatocellular carcinoma in Europe, 1980‐2004 , 2008, Hepatology.

[288]  J. Llovet,et al.  Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. , 2008, Journal of hepatology.

[289]  K. Tsoi,et al.  Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma , 2008, Alimentary pharmacology & therapeutics.

[290]  Y. Shiratori,et al.  Cost‐effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances , 2008, Journal of gastroenterology and hepatology.

[291]  D. Hasenclever,et al.  Should Treatment of Hepatitis B Depend on Hepatitis B virus Genotypes? A Hypothesis Generated from an Explorative Analysis of Published Evidence , 2008, Antiviral therapy.

[292]  M. Jonas,et al.  Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B , 2008, Hepatology.

[293]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[294]  T. Fujii,et al.  Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. , 2008, JAMA.

[295]  R. Bruno,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults , 2008, HIV medicine.

[296]  Luigi Solbiati,et al.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? , 2007, Hepatology.

[297]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[298]  Giovanni Simonetti,et al.  Percutaneous Cryoablation of Small Hepatocellular Carcinoma with US Guidance and CT Monitoring: Initial Experience , 2008, CardioVascular and Interventional Radiology.

[299]  J. Hoofnagle,et al.  Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy , 2008, Annals of Internal Medicine.

[300]  J. Desenclos,et al.  Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. , 2008, Journal of hepatology.

[301]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[302]  S. Rafii,et al.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[303]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[304]  J. Bruix,et al.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma , 2007, Hepatology.

[305]  William M. Lee,et al.  Acute liver failure: Summary of a workshop , 2007, Hepatology.

[306]  P. Marcellin,et al.  HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B , 2008, Hepatology.

[307]  G. Lau,et al.  Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B , 2008, Hepatology international.

[308]  H. Yoshida,et al.  Neoplastic Seeding After Radiofrequency Ablation for Hepatocellular Carcinoma , 2008, The American Journal of Gastroenterology.

[309]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[310]  M. Makuuchi,et al.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.

[311]  J. Emond,et al.  Donor morbidity after living donation for liver transplantation. , 2008, Gastroenterology.

[312]  M. Sulkowski,et al.  Viral hepatitis and HIV coinfection. , 2008, Journal of hepatology.

[313]  L. Bolondi,et al.  Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population , 2009, Annals of Surgical Oncology.

[314]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[315]  Eva Pagano,et al.  Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial , 2008, Scandinavian journal of gastroenterology.

[316]  M. Jonas,et al.  Long‐term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety , 2007, Journal of viral hepatitis.

[317]  J. Trotter,et al.  Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[318]  M. Manns,et al.  Immunotherapy of HCC. , 2008, Reviews on recent clinical trials.

[319]  Zongli Zhang,et al.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. , 2008, JAMA.

[320]  P. Marcellin,et al.  Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a , 2009, Antiviral therapy.

[321]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[322]  R. Bartenschlager,et al.  Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference , 2009, Hepatology.

[323]  E. Steyerberg,et al.  Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.

[324]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[325]  Mary Ann Comunale,et al.  Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma , 2009, Cancer Epidemiology Biomarkers & Prevention.

[326]  Huy A. Nguyen,et al.  Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil , 2009, Hepatology.

[327]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[328]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[329]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[330]  H. Rhim,et al.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.

[331]  Jeffrey S. Morris,et al.  Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[332]  Hung‐Chih Yang,et al.  Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled study , 2009, Journal of viral hepatitis.

[333]  A. Burroughs,et al.  Current management of hepatitis B virus infection before and after liver transplantation , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[334]  A. Horvath,et al.  Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. , 2009, Clinical chemistry.

[335]  M. Buti,et al.  Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients , 2009, The American Journal of Gastroenterology.

[336]  N. Kato,et al.  Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C , 2009, Hepatology international.

[337]  N. Kato,et al.  Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography , 2009, Hepatology.

[338]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[339]  Marek Ancukiewicz,et al.  Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[340]  R. Makuch,et al.  Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. , 2009, Journal of hepatology.

[341]  L. Castéra.  Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis , 2009, Journal of viral hepatitis.

[342]  P. Marcellin,et al.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.

[343]  William M. Lee,et al.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. , 2009, Gastroenterology.

[344]  Pierre Bedossa,et al.  Non‐invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[345]  Y. N. Park,et al.  The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. , 2009, Journal of hepatology.

[346]  J. Marrero,et al.  Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis , 2009, Alimentary pharmacology & therapeutics.

[347]  L. Keltner,et al.  A phase I/II safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[348]  G. Carosi,et al.  Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. , 2009, Journal of hepatology.

[349]  J. Llovet,et al.  A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. , 2009, Gastroenterology.

[350]  P. Marcellin,et al.  924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP , 2009 .

[351]  Soonmyung Paik,et al.  Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.

[352]  J. Bruix,et al.  Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma , 2009, Hepatology.

[353]  M. Colombo,et al.  A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. , 2009, Gastroenterology.

[354]  L. Forzenigo,et al.  The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis , 2009, Gut.

[355]  B. Sangro,et al.  Treatment of Hepatocellular Carcinoma by Radioembolization Using 90Y Microspheres , 2009, Digestive Diseases.

[356]  Jordi Rimola,et al.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.

[357]  K. Soo,et al.  Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. , 2009, The Cochrane database of systematic reviews.

[358]  E. Vicaut,et al.  Radiofrequency ablation of hepatocellular carcinoma: Long‐term results and prognostic factors in 235 Western patients with cirrhosis , 2009, Hepatology.

[359]  T. López-Cuadrado,et al.  Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma , 2009, BMC gastroenterology.

[360]  M. Mondelli,et al.  Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. , 2009, Journal of hepatology.

[361]  E. Raymond,et al.  Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. , 2009, The Lancet. Oncology.

[362]  Robert Ford,et al.  Individual patient data analysis to assess modifications to the RECIST criteria. , 2009, European journal of cancer.

[363]  Wolfgang Sadee,et al.  A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas , 2009, Clinical Cancer Research.

[364]  Stephanie Roessler,et al.  MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.

[365]  U. Mihm,et al.  Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function , 2009, Hepatology.

[366]  R. Stasi,et al.  Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[367]  C. Fuchs,et al.  Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. , 2009, The oncologist.

[368]  T. Asselah,et al.  High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. , 2009, Journal of hepatology.

[369]  K. Boudjema,et al.  Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. , 2009, World journal of gastroenterology.

[370]  M. Abecassis,et al.  Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium‐90 microspheres , 2009, Hepatology.

[371]  L. Mariani,et al.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.

[372]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[373]  J. Llovet,et al.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. , 2010, Annual review of medicine.

[374]  G. Abou-Alfa,et al.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. , 2010, JAMA.

[375]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[376]  S. Arii,et al.  Surgical Strategies for Hepatocellular Carcinoma with Special Reference to Anatomical Hepatic Resection and Intraoperative Contrast-Enhanced Ultrasonography , 2010, Oncology.

[377]  F. Carrat,et al.  Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. , 2010, Journal of hepatology.

[378]  R. Idilman,et al.  Natural history and treatment of chronic delta hepatitis , 2010, Journal of viral hepatitis.

[379]  C. Boucher,et al.  Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.

[380]  R. D. de Man,et al.  Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B * , 2010, Journal of viral hepatitis.

[381]  K. Croome,et al.  Laparoscopic vs open hepatic resection for benign and malignant tumors: An updated meta-analysis. , 2010, Archives of surgery.

[382]  Y. Paik,et al.  Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg‐positive chronic hepatitis B , 2010, Hepatology.

[383]  G. Bodoky,et al.  Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). , 2010, The oncologist.

[384]  Ching-Lung Lai,et al.  Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[385]  Sharon I. Greenblum,et al.  Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma , 2010, Hepatology.

[386]  H. Janssen,et al.  Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. , 2010, Gastroenterology.

[387]  Chiun Hsu,et al.  Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. , 2010, Journal of hepatology.

[388]  R. D. de Man,et al.  Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. , 2010, Gastroenterology.

[389]  Liver allocation for patients with hepatocellular carcinoma , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[390]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[391]  M. Manns,et al.  13 TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B – VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN) , 2010 .

[392]  E. Raymond,et al.  [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.

[393]  J. Ertle,et al.  Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival , 2010, Hepatology.

[394]  M. Manns,et al.  Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics , 2010, Journal of Clinical Microbiology.

[395]  D. Samuel,et al.  Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[396]  Derek Y. Chiang,et al.  IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. , 2010, Journal of hepatology.

[397]  Ghazi Hussain,et al.  Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony , 2010, Current hepatitis reports.

[398]  Kurinchi Gurusamy,et al.  Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. , 2010, Journal of hepatology.

[399]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[400]  R. Freeman,et al.  Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[401]  M. Buti,et al.  Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. , 2010, Journal of hepatology.

[402]  K. Simon,et al.  Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels , 2010, Hepatology.

[403]  M. Volk,et al.  A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[404]  F. Dabis,et al.  Concentrations of Tenofovir and Emtricitabine in Breast Milk of HIV-1-Infected Women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2 , 2010, Antimicrobial Agents and Chemotherapy.

[405]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[406]  M. Manns,et al.  Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients , 2010, Hepatology.

[407]  A. Andriulli,et al.  Outcome of chronic delta hepatitis in Italy: a long-term cohort study. , 2010, Journal of hepatology.

[408]  V. Wong,et al.  Durability of peginterferon alfa‐2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[409]  A. Burroughs,et al.  Liver grafts from anti-hepatitis B core positive donors: a systematic review. , 2010, Journal of hepatology.

[410]  D. Harnois.  The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis , 2010 .

[411]  E. Schiff,et al.  Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B , 2010, Hepatology.

[412]  M. Volk,et al.  Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost‐benefit analysis while awaiting data on sorafenib safety , 2010, Hepatology.

[413]  Yang Guo,et al.  Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. , 2010, Cancer research.

[414]  A. Lok,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. , 2010, Journal of hepatology.

[415]  V. Mazzaferro,et al.  The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[416]  T. Berg,et al.  Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues , 2010, Hepatology.

[417]  S. Pungpapong,et al.  28 EMTRICITABINE/TENOFOVIR DF COMBINATION +/− HBIG POST-ORTHOTOPIC LIVER TRANSPLANTATION TO PREVENT HEPATITIS B RECURRENCE IN PATIENTS WITH NORMAL TO MODERATE RENAL IMPAIRMENT: INTERIM RESULTS , 2010 .

[418]  G. Abou-Alfa,et al.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[419]  H. Lee,et al.  Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. , 2010, Journal of hepatology.

[420]  Xiaomao Li,et al.  Lamivudine in Late Pregnancy to Interrupt In Utero Transmission of Hepatitis B Virus: A Systematic Review and Meta-Analysis , 2010, Obstetrics and gynecology.

[421]  S. Thongprasert,et al.  Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. , 2010 .

[422]  Joan M. Block,et al.  Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options , 2010, Hepatology.

[423]  P. Keegan,et al.  Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. , 2010, Journal of the National Cancer Institute.

[424]  T. Berg,et al.  Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. , 2010, Gastroenterology.

[425]  Yong Zeng,et al.  A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.

[426]  J. Dufour,et al.  Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. , 2010, The oncologist.

[427]  T. Roskams,et al.  Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. , 2010, Seminars in liver disease.

[428]  B. Bacon,et al.  Meta‐analysis: re‐treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy , 2010, Alimentary pharmacology & therapeutics.

[429]  J. Bruix,et al.  A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma , 2010, Hepatology.

[430]  R. Lencioni.  Loco‐regional treatment of hepatocellular carcinoma , 2010, Hepatology.

[431]  P. Marcellin,et al.  Transient elastography in chronic viral hepatitis: a critical appraisal , 2011, Gut.

[432]  F. Farinati,et al.  Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function , 2011, Cancer Chemotherapy and Pharmacology.

[433]  K. Gurusamy,et al.  Which matters most: Number of tumors, size of the largest tumor, or total tumor volume? , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[434]  U. Nöthlings,et al.  Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. , 2011, Journal of the National Cancer Institute.

[435]  Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[436]  Arthur Liberzon,et al.  Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. , 2011, Gastroenterology.

[437]  William M. Lee,et al.  Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. , 2011, Gastroenterology.

[438]  D. Lu,et al.  CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[439]  M. Thomas,et al.  Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.

[440]  J. Wetterslev,et al.  Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. , 2011, The Cochrane database of systematic reviews.

[441]  J. McCall,et al.  Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. , 2011, Journal of hepatology.

[442]  F. Zoulim,et al.  Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.

[443]  S. Belknap,et al.  Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[444]  M. Yuen,et al.  Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety , 2011, The American Journal of Gastroenterology.

[445]  F. Branchi,et al.  The role of transient elastography in patients with hepatitis B viral disease. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[446]  V. Vilgrain,et al.  Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3‐ and 6‐month periodicities , 2011, Hepatology.

[447]  Wei Zhao,et al.  A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. , 2011, Journal of hepatology.

[448]  M. Yuen,et al.  Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. , 2011, Gastroenterology.

[449]  G. Raimondo,et al.  Hepatocellular carcinoma: the point of view of the hepatitis B virus. , 2011, Carcinogenesis.

[450]  Tim Meyer,et al.  EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.

[451]  T. Saibara,et al.  Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[452]  M. Colombo,et al.  Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy , 2011, Hepatology.

[453]  M. Manns,et al.  [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. , 2011, Zeitschrift fur Gastroenterologie.

[454]  G. Touloumi,et al.  Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study , 2011, Gut.

[455]  Y. N. Park,et al.  Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) , 2011, Hepatology.

[456]  M. Buti,et al.  Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease , 2011, Hepatology.

[457]  M. Kumar,et al.  Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute‐on‐chronic liver failure , 2011, Hepatology.

[458]  Y. Liaw,et al.  Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study , 2011, Hepatology.

[459]  P. Marcellin,et al.  Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C , 2011, Hepatology.

[460]  D. Harnois,et al.  Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .

[461]  P. Marcellin,et al.  Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients , 2013, Hepatology International.

[462]  D. Harnois.  Excess Mortality in Patients with Advanced Chronic Hepatitis C Treated with Long-Term Peginterferon , 2011 .

[463]  Derek Y. Chiang,et al.  MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. , 2011, Gastroenterology.

[464]  D. Harnois.  Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta , 2011 .

[465]  X. Forns,et al.  Noninvasive assessment of liver fibrosis , 2011, Hepatology.

[466]  최기홍,et al.  Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis , 2011 .

[467]  V. Mazzaferro,et al.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. , 2011, Cancer treatment reviews.

[468]  S. Ahn,et al.  Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir , 2011, Hepatology.

[469]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[470]  M. Buti,et al.  Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response , 2011, Hepatology.

[471]  S. Caldwell,et al.  Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[472]  Hong-wei Zhang,et al.  A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. , 2011, World journal of gastroenterology.

[473]  M. Kudo,et al.  Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[474]  M. Kudo,et al.  Effect of vitamin K2 on the recurrence of hepatocellular carcinoma , 2011, Hepatology.

[475]  E. Cholongitas,et al.  Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. , 2011, Journal of hepatology.

[476]  S. Truant,et al.  Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child‐Pugh score , 2011, Alimentary pharmacology & therapeutics.

[477]  M. Buti,et al.  740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS , 2011 .

[478]  S. Fan,et al.  High-Intensity Focused Ultrasound for Hepatocellular Carcinoma: A Single-Center Experience , 2011, Annals of surgery.

[479]  P. Marcellin,et al.  69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS , 2011 .

[480]  Y. Rolland,et al.  Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma , 2012, Cancer.

[481]  K. Öberg.  Implications for Clinical Practice and Trial Design , 2012 .

[482]  P. Lampertico,et al.  Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. , 2012, Journal of hepatology.

[483]  T. Asselah,et al.  Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[484]  Patrick M M Bossuyt,et al.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. , 2012, The Lancet. Oncology.